study to compaire the role of Ayurvedic and modern medicine in CKD.

Phase 3

Not yet recruiting

• Conditions: Chronic kidney disease, stage 3 (moderate),

• Registration Number: CTRI/2022/07/043780
• Lead Sponsor: MGACRC

Brief Summary

current study is the double blind randomized controlled clinical trial.

purpose of study:

Chronic kidney disease (CKD) is a global health problem that costs health systems a lot of

money, and  also a risk factor for cardiovascular disease (CVD).

CKD is linked to an increased risk of cardiovascular morbidity, premature mortality, and/or a

lower quality of life at all stages. In modern science management of Chronic kidney disease.

mainly includes supportive treatment, use of diuretics and in severe cases dialysis or renal

transplant. But all these treatment has their own limitations like high cost, adverse effects as well

as complications. In Ayurveda many herbal formulations having Mutral (diuretic) and Rasayana

(rejuvenating) properties are recommended in the management of Mutravikaras like Mutraghata

(chronic kidney disease). Various research studies conducted on herbal drugs in mutravikaras are

available showing their efficacy 7,8,9. BruhtyadiKwath possesses diuretic, rejuvenating, antibacterial

and anti-inflammatory properties. Research studies are conducted on Bruhatyadikwath in the

management of Mutrakruchra but no study conducted on Mutraghata. So for early stage

prevention and to check further progression this study is planned along with furosemide to

evaluate the efficacy of BruhtyadiKwathfor improving e-GFR and Albuminuria in Chronic

Kidney Disease.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2022-06-07
• Study Start: 2022-07-20

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• 1.age 20years to 70 years.
• diagnosed patient of CKD (BEST on eGFR,and Albuminuria clinically stable patient of stage 1to3 will be included stage 1- GFR>90.
• stage2- gfr between 60 to 89 stage 3-3a.eGFR 45TO<60 3b.eGFR 30 TO<45.

Exclusion Criteria

• 1.post renal transplant.
• known case of HIV patients or subjects or subjects on immune suppressive drug.
• pregnant and lactating femeles.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
2.To access the efficacy of bruhtyadi kwath with furosemide on symptomes, eGFR and albuminuria chronic Kidney disease.	Assessment will be reported on baseline, 30th day, 60 th day,&90th day on the basis of subjective & objective parameters
1.To access the efficacy of bruhatyadi kwath on symptoms,e GFR,and Albuminuria in Chronic Kidney Disease.	Assessment will be reported on baseline, 30th day, 60 th day,&90th day on the basis of subjective & objective parameters
3.To access the efficacy of furosemide on symptoms, eGFR And albuminuria in chronic kidney disease	Assessment will be reported on baseline, 30th day, 60 th day,&90th day on the basis of subjective & objective parameters
4.To compare the effect of above therapy in various stages of chronic kidney disease.	Assessment will be reported on baseline, 30th day, 60 th day,&90th day on the basis of subjective & objective parameters

Trial Locations

Locations (1)

Mahatma Gandhi Ayurved Collage Hospital And Research Centre; 🇮🇳 Wardha, MAHARASHTRA, India

Mahatma Gandhi Ayurved Collage Hospital And Research Centre

🇮🇳Wardha, MAHARASHTRA, India

Dr Namrata Shankarpure

Principal investigator

8850033874

namrataashankarpure@gmail.com